U.S. National Institutes of Health
U.S. National Institutes of Health


IDRankTitleRecruitmentStudy ResultsConditionsInterventionsURL
2922129221Safety and Efficacy of Berodual® Inhaled Via Respimat® Compared to MDI (Metered Dose Inhaler) in Pediatric Patients With AsthmaCompletedNo Results AvailableAsthmaDrug: Berodual® Respimat®, low dose|Drug: Berodual® Respimat®, high dose|Drug: Berodual® MDIhttps://ClinicalTrials.gov/show/NCT02182505
2922229222Efficacy of Macrolide and Glucocorticoid in the Treatment of Chronic Rhinosinusitis Patients After Endoscopic Sinus Surgery ( ESS)RecruitingNo Results AvailableChronic Rhinosinusitis|Endoscopic Sinus SurgeryDrug: Clarithromycin|Drug: Glucocorticoidhttps://ClinicalTrials.gov/show/NCT02182492
2922329223Safety and Efficacy of Berodual® Respimat® Compared to Berodual® MDI (Metered Dose Inhaler) in Asthma PatientsCompletedNo Results AvailableAsthmaDrug: Berodual® via Respimat®, high dose|Drug: Berodual® via Respimat®, low dose|Drug: Berodual® via MDI, high dose|Drug: Placebo Respimat®|Drug: Placebo MDIhttps://ClinicalTrials.gov/show/NCT02182479
2922429224German Colon Capsule RegistryActive, not recruitingNo Results AvailableColon Cancer|Colon Polyp|Diarrhea|Inflammatory Bowel System|Ulcerative ColitisDevice: Colon capsule endoscopyhttps://ClinicalTrials.gov/show/NCT02182466
2922529225Single Rising Oral Doses of BI 10773 in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BI 10773 - single rising dose|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02182453
2922629226A Safety, Tolerability, Efficacy and QoL Study of Human recAP in the Treatment of Patients With SA-AKIRecruitingNo Results AvailableAcute Kidney InjuryBiological: recAP|Other: Placebohttps://ClinicalTrials.gov/show/NCT02182440
2922729227Malnutrition Clinical Characteristics Validation StudyEnrolling by invitationNo Results AvailableMalnutritionhttps://ClinicalTrials.gov/show/NCT02182427
2922829228Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy VolunteersCompletedNo Results AvailableHealthyDrug: BI 207127 NA (TF-I)|Drug: BI 207127 NA (TF-II)|Drug: BI 207127 NA delayed release|Drug: BI 207127 NA extended release (10% HPMC)|Drug: BI 207127 NA extended release (15% PEO)|Drug: BI 207127 NA extended release (20% HPMC)https://ClinicalTrials.gov/show/NCT02182414
2922929229Multiple Doses of BI 207127 NA, BI 201335 NA Followed by the Combination of BI 207127 NA and BI 201335 NA in Healthy Male VolunteersTerminatedNo Results AvailableHealthyDrug: BI 207127 NA|Drug: BI 201335 NA|Drug: Midazolam|Drug: Tolbutamidehttps://ClinicalTrials.gov/show/NCT02182401
2923029230Single Rising Oral Doses of BI 207127 NA as Powder in the Bottle in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: Placebo|Drug: BI 207127 NA powder for solution|Drug: BI 207127 NA tablethttps://ClinicalTrials.gov/show/NCT02182388
2923129231Effect of BI 201335 Mediated UGT1A1 (Uridine-diphosphate-glucuronosyltransferases) Inhibition in Healthy VolunteersCompletedNo Results AvailableHealthyDrug: BI 201335 NA|Drug: Raltegravirhttps://ClinicalTrials.gov/show/NCT02182375
2923229232Safety, Tolerability and Pharmacokinetics of Multiple Rising Doses of BI 201335 NA in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: BI 201335 NA|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02182362
2923329233Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BI 201335 NA soft gelatin capsule|Drug: [14C]-BI 201335 NA radiolabelled drughttps://ClinicalTrials.gov/show/NCT02182349
2923429234Effects of BI 201335 NA on Cytochrome P450 and P-glycoprotein Activity Using a Probe Drug Cocktail in Healthy VolunteersCompletedNo Results AvailableHealthyDrug: BI 201335 NA|Drug: Caffeine|Drug: Warfarin sodium|Drug: Vitamin K|Drug: Omeprazole|Drug: Dextromethorphan hydrobromide|Drug: Midazolam HCl solution|Drug: Midazolam HCl oral syrup|Drug: Digoxinhttps://ClinicalTrials.gov/show/NCT02182336
2923529235Safety, Tolerance, and Pharmacokinetics of Single Oral Doses of BI 201335 NA and Bioavailability in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: BI 201335 NA|Drug: Placebo solutionhttps://ClinicalTrials.gov/show/NCT02182323
2923629236Assessment of the Effect of BI 201335 on the QT Interval in Healthy Female and Male SubjectsCompletedNo Results AvailableHealthyDrug: BI 201335 low dose|Drug: BI 201335 placebo|Drug: Moxifloxacin|Drug: BI 201335 high dosehttps://ClinicalTrials.gov/show/NCT02182310
2923729237Safety, Tolerability, and Pharmacokinetics of BI 201335 NA in Healthy Male SubjectsCompletedNo Results AvailableHealthyDrug: BI 201335 NA in single rising doses|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02182297
2923829238Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy VolunteersCompletedNo Results AvailableHealthyDrug: low dose BI 201335 NA soft gelatine capsule (SGC)|Drug: high dose BI 201335 NA soft gelatine capsule (SGC)|Drug: low dose BI 201335 NA powder in bottle (PIB)|Drug: high dose BI 201335 NA powder in bottle (PIB)https://ClinicalTrials.gov/show/NCT02182284
2923929239Single Rising Dose Study of BI 201335 ZW in Healthy Male SubjectsTerminatedNo Results AvailableHealthyDrug: BI 201335 ZW - single rising dose|Drug: Placebohttps://ClinicalTrials.gov/show/NCT02182271
2924029240Safety and Tolerability Study of BIBF 1120 as Intravenous Infusion and Absolute Bioavailability of BIBF 1120 as Soft Gelatine Capsule in Healthy SubjectsCompletedNo Results AvailableHealthyDrug: BIBF 1120 soft gelatine capsule|Drug: BIBF 1120 intravenous solution|Drug: Placebo ampoulehttps://ClinicalTrials.gov/show/NCT02182258
2924129241Dose Escalation Study of BIBF 1120 in Patients With Advanced Gynaecological MalignanciesCompletedNo Results AvailableGenital Neoplasms, FemaleDrug: BIBF 1120|Drug: Paclitaxel|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT02182245
2924229242A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedNo Results AvailableCarcinoma, Non-Small-Cell LungDrug: BIBF 1120|Drug: Paclitaxel|Drug: Carboplatinhttps://ClinicalTrials.gov/show/NCT02182232
2924329243Oral Treatment With BIBF 1120 Together With Docetaxel and Prednisone in Patients With Hormone Refractory Prostate CancerCompletedNo Results AvailableProstatic NeoplasmsDrug: BIBF 1120https://ClinicalTrials.gov/show/NCT02182219
2924429244An Dose Escalation Study of Treatment With BIBF 1120 in Patients With Advanced Solid TumoursCompletedNo Results AvailableTumorsDrug: BIBF 1120https://ClinicalTrials.gov/show/NCT02182206
2924529245Safety and Relative Bioavailability of BIBF 1120 Soft Gelatine Capsules Charge 1, BIBF 1120 Soft Gelatine Capsules Charge 2 and BIBF 1120 Drinking Solution in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BIBF 1120 capsules charge 1|Drug: BIBF 1120 capsules charge 2|Drug: BIBF 1120 drinking solutionhttps://ClinicalTrials.gov/show/NCT02182193
2924629246SCCI Tissue and Data Repository ProtocolNot yet recruitingNo Results AvailableCritical Illnesshttps://ClinicalTrials.gov/show/NCT02182180
2924729247A Trial Of Intravenous N-Acetylcysteine In The Management Of Antituberculous Drug-Induced HepatitisRecruitingNo Results AvailableDrug-Induced Liver InjuryDrug: IV N-acetylcysteine (NAC)|Drug: Waterhttps://ClinicalTrials.gov/show/NCT02182167
2924829248Metabolism and Pharmacokinetics of [14C]-BIBF 1120 in Healthy Male VolunteersCompletedNo Results AvailableHealthyDrug: BIBF 1120 EShttps://ClinicalTrials.gov/show/NCT02182154
2924929249An Dose Escalation Study of BIBF 1120 Administered in Patients With Relapsed or Refractory Multiple MyelomaCompletedNo Results AvailableMultiple MyelomaDrug: BIBF 1120 EShttps://ClinicalTrials.gov/show/NCT02182141
2925029250A Dose-escalation Study of BIBF 1120 in Japanese Patients With Advanced Solid TumoursCompletedNo Results AvailableTumorsDrug: BIBF 1120https://ClinicalTrials.gov/show/NCT02182128

* Görseller ve İçerik tekif hakkına sahip olabilir